360 related articles for article (PubMed ID: 9409315)
1. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Byrne A; Moran N; Maher M; Walsh N; Crean P; Fitzgerald DJ
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3224-9. PubMed ID: 9409315
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
Akkerhuis KM; van Den Brand MJ; van Der Zwaan C; Peels HO; Suryapranata H; van Der Wieken LR; Stibbe J; Hoffmann J; Baardman T; Deckers JW; Simoons ML
Heart; 2001 Apr; 85(4):444-50. PubMed ID: 11250974
[TBL] [Abstract][Full Text] [Related]
3. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.
Kearney D; Byrne A; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2004 Feb; 43(4):526-31. PubMed ID: 14975458
[TBL] [Abstract][Full Text] [Related]
4. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
Müller TH; Weisenberger H; Brickl R; Narjes H; Himmelsbach F; Krause J
Circulation; 1997 Aug; 96(4):1130-8. PubMed ID: 9286940
[TBL] [Abstract][Full Text] [Related]
5. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.
Catella-Lawson F; Kapoor S; Moretti D; De Marco S; Vigilante GJ; Cucchiara AJ; Ramsey KE; Combe S; Rocca B; Theroux P; FitzGerald GA;
Am J Cardiol; 2001 Aug; 88(3):236-42. PubMed ID: 11472700
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
8. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Kereiakes DJ; Kleiman NS; Ambrose J; Cohen M; Rodriguez S; Palabrica T; Herrmann HC; Sutton JM; Weaver WD; McKee DB; Fitzpatrick V; Sax FL
J Am Coll Cardiol; 1996 Mar; 27(3):536-42. PubMed ID: 8606262
[TBL] [Abstract][Full Text] [Related]
10. Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty.
Dai H; Chen J; Tao Q; Zhu J; Zhang F; Zheng L; Qiu Y
Postgrad Med J; 2003 Sep; 79(935):522-6. PubMed ID: 13679549
[TBL] [Abstract][Full Text] [Related]
11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
12. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Schulman SP; Goldschmidt-Clermont PJ; Topol EJ; Califf RM; Navetta FI; Willerson JT; Chandra NC; Guerci AD; Ferguson JJ; Harrington RA; Lincoff AM; Yakubov SJ; Bray PF; Bahr RD; Wolfe CL; Yock PG; Anderson HV; Nygaard TW; Mason SJ; Effron MB; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt MM; Gerstenblith G
Circulation; 1996 Nov; 94(9):2083-9. PubMed ID: 8901655
[TBL] [Abstract][Full Text] [Related]
13. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
[TBL] [Abstract][Full Text] [Related]
14. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
[TBL] [Abstract][Full Text] [Related]
15. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
16. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty.
Ciabattoni G; Ujang S; Sritara P; Andreotti F; Davies G; Simonetti BM; Patrono C; Maseri A
J Am Coll Cardiol; 1993 May; 21(6):1377-81. PubMed ID: 8473644
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
[TBL] [Abstract][Full Text] [Related]
18. Fradafiban. BIBU 52, BIBU 52 ZW.
Drugs R D; 1999 May; 1(5):377-8. PubMed ID: 10566068
[No Abstract] [Full Text] [Related]
19. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
20. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.
Ellis SG; Tcheng JE; Navetta FI; Muller DW; Weisman HF; Smith C; Anderson KM; Califf RM; Topol EJ
Coron Artery Dis; 1993 Feb; 4(2):167-75. PubMed ID: 8269208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
